If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

A Bloomberg report has claimed even businesses which have purchased Copilot plans are struggling to convince users to make the switch, with drugmaker Amgen buying a 20,000 user plan, only to have ...

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Buoyed by strong returns for shares of Salesforce and American Express, the Dow Jones Industrial Average is rallying Tuesday afternoon. The Dow is trading 591 points (1.4%) higher, as shares of ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...